Prognostic factors in first-line atezolizumab-bevacizumab treatment of intermediate or advanced hepatocellular carcinoma
Kyowon Gu, Tae Wook Kang, Jaeseung Shin, Dong Hyun Sinn, Myung Ji Goh, Jung Yong Hong, Sangah Chi · 2026
Read Prognostic factors in first-line atezolizumab-bevacizumab treatment of intermediate or advanced hepatocellular carcinoma by Kyowon Gu, Tae Wook Kang, Jaeseung Shin, Dong Hyun Sinn, Myung Ji Goh, Jung Yong Hong, Sangah Chi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13412060.txt.
Description
Kyowon Gu and colleagues search in 2026 for traits that predict how long liver cancer patients stay free of progression on a first-line drug pair. The pair, atezolizumab plus bevacizumab, is a standard opening treatment for intermediate or advanced hepatocellular carcinoma. Charts and pre-treatment MRI scans covered 47 patients treated between September 2020 and July 2022.
During follow-up, 33 patients saw their tumours progress, and the median progression-free span was 4.3 months in this group. Younger age, tumours spanning ten centimetres or more, and a bright rim pattern around the tumour on MRI each pointed to earlier progression. Patients who also received radiotherapy fared better on this measure, a link the authors say merits closer study.
Catalog record
| CREATOR | Kyowon Gu, Tae Wook Kang, Jaeseung Shin, Dong Hyun Sinn, Myung Ji Goh, Jung Yong Hong, Sangah Chi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |